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Glomerular immune injury in the rat: The influence of angiotensin II
and a-adrenergic inhibitors. Nephron filtration rate (SNGFR) decreases
significantly after the administration of large doses of antiglomerular
basement membrane antibody (anti-GBM) as a result of reductions in
both nephron (renal) plasma flow (RPF) and the glomerular permeabili-
ty coefficient (LA). We have examined the participation of angiotensin
II (All) and c-adrenergic activity in this process in paired studies in
three groups of Munich-Wistar rats: group I, control and untreated;
group 2, rats receiving continuous infusion of sar'-ala8-AI1 (1 i.g kg of
body wt' min'), an All receptor antagonist; and group 3, rats
receiving continuous infusion of phentolamine (27 ig . kg body wt'
min), a dose sufficient to block ct-adrenergic responses. In group I,
SNGFR decreased from 58 4 to 35 6 nI min' g kidney wt '(P <
0.001) after anti-GBM administration due to reductions in RPF (272
35tol70±52nl.min.gofkidneywu',P<o.oool)andLA(o.l3±0.03 to 0.04 0.01 nl sec' g of kidney wt mm Hg', P <0.02). In
group 2, the sar'-ala8-Al I-infused rats, SNGFR decreased to a greater
extent than it did in group 1 (P < 0.0l)(55 2 to 18 6nI . min' gof
kidney wF', P <0.005) due to a greater reduction in RPF and a similar
decrease in LA. In group 3, phentolamine infusion prevented the
decrease in SNGFR (52 3 to 52 4 nI min' g of kidney wt', NS)
due primarily to elimination of vasoconstriction and a significantly
lesser reduction in LA (0.10 0.02 to 0.07 0.01 nI sec g of
kidney wt mm Hg'). There were no morphologic differences after
anti-GBM administration that were unique to group 3. Blockade of All
activity does not prevent immune induced vasoconstriction or the
reduction in LA. ci-Adrenergic blockade (1) prevents acute immune
induced vasoconstriction and (2) partially prevents the immune induced
reduction in LA.
Lesion glomerulaire immunologique chez le rat. Influence des inhibi-
teurs de l'angiotensine II et oi-adrenergique. Le debit de filtration
glomerulaire individuel (SNGFR) diminue significativement aprés l'ad-
ministration de fortes doses d'anticorps antimembrane basale (anti-
GBM) glomerulaire en raison de Ia diminution du debit plasmatique
(RPF) et du coefficient de perméabilité glomerulaire (LA). Nous avons
étudié Ia participation de l'angiotensine II (All) et de I'activité cx-
adrénergique dans ce processus chez trois groupes de rats Munich-
Wistar: groupe I, contrôles et non traitCs; groupe 2, des rats recevant
une perfusion continue de sar'-ala8-A11 (1 p.g kg of body wt' min),
un antagoniste des rCcepteurs de l'AII; et groupe 3, des rats recevant
une perfusion continue de phentolamine (27 g kg of body wt'
min), une dose suffisante pour bloquer les réponses cs-adrënergiques.
Dans le groupe I, SNGFR diminue de 58 4 a 35 6 nI mm' g of
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kidney wt, (P < 0,001) apres anticorps anti-GBM du fait de Ia
diminution de RPF (272 35 ii 170 52 nI min g of kidney wt, P
<0,0001)et LA (0,13 0,03 a 0,04 0,01 n1 sec g of kidney wt1•
mm Hg', P <0,02). Dans Ic groupe 2, chez les rats perfuses avec sar'-
ala8-AII, SNGFR a diminuC plus que dans Ic groupe I (P <0,01) (55 2
a 18 6 nI min' g of kidney wt, P < 0,005) du fait d'une plus
grande diminution de RPF et d'une diminution semblable de LA. Dans
le groupe 3, Ia perfusion de phentolamine a empéché La diminution de
SNGFR(52 3 a 52 4 nI min' g of kidney wt, NS) du fait de
l'élimination de la vasoconstriction et d'une diminution significative-
mentmoindrede LA(0,l0 0,02a0,07 0,01 nlsec' gofkidney
wr' mm Hg'). II n'a pas etC observe de differences morphologiques
particulieres en groupe 3 aprés anticorps anti-GBM. Le blocage de
l'activitC de All n'empêche pas Ia vasoconstriction a dCterminisme
immun ou Ia reduction de LA. Le blocage cs-adrCnergique (1) empéche
Ia vasodilatation aiguë a déterminisme immun et (2) empeche partielle-
ment Ia reduction de LA a dCterminisme immun.
We have previously demonstrated that within 1 hour of the
administration of large quantities of antiglomerular basement
membrane antibody (anti-GBM) to rats, the single nephron
filtration rate (SNGFR) decreases significantly, due to major
reductions in both nephron plasma flow (RPF) and the glomeru-
lar permeability coefficient (LA) [1, 2]. More recent studies
have demonstrated that the vasoconstriction leading to reduc-
tions in RPF was almost totally complement dependent [2]. A
major unresolved issue remains—the mechanism whereby this
complement dependent vasoconstriction is mediated. There are
very few candidates for the vasoconstrictive mediator of this
reduction in nephron plasma flow. Candidates include the major
renal vasoconstrictor systems, the renin-angiotension system,
and the adrenergic system. Other less well defined vasocon-
strictors such as adenine nucleotides and certain vasoconstric-
tor prostaglandins could also participate. An alternative possi-
bility, is that no intermediary vasoconstrictor systems partici-
pate in the reduction in RPF, but rather certain complement
components directly produce the vasoconstriction.
The present studies were designed to examine the influence
of inhibition of the two major vasoconstrictor systems upon the
mechanisms leading to glomerular immune injury following
anti-GBM administration. Continuous infusions of the angioten-
sin II (All) receptor blocker sarLala8AII and the cs-adrenergic
antagonist phentolamine permitted evaluation of the potential
role of these respective vasoconstrictor substances in the
process of glomerular immune injury. Delineation of the respec-
452
All and cx-adrenergic ijhihiiors and anti-GBM injury 453
tive pathogenetic roles of the two vasoconstrictor systems has
been accomplished and the results suggest that (1) the alpha
adrenergic system mediates acute immune vasoconstriction and
that (2) blockade of a-adrenergic activity at least partially
prevents a reduction in LA following glomerular immune
injury, But infusion of the All receptor blocker sar1-ala8-A1I
appears to augment the vasoconstriction associated with the
infusion of anti-GBM antibody.
Methods
Experiment animals. The current studies were performed on
Munich-Wistar rats (190 to 250 g of body wt), bred and
maintained in a colony housed at the Animal Research Facility
at the San Diego Veterans Administration Medical Center, San
Diego, California.
Preparation of anti-GBM antibody. This was produced by
immunizing rabbits repeatedly with 10 to 20 mg of rat GBM in
complete Freund's adjuvant. Rat GBM was prepared by a
modification of the method of Krakower and Greenspon 131.
The attainment of nephrotoxic levels of anti-GBM was recog-
nized when the i.v. injection of rabbit serum induced acute
proteinuria in rats. Rabbit serum was then collected, pooled,
absorbed with rat plasma and peripheral blood cells, and the
gamma globulin fraction separated and concentrated by precipi-
tation at a final concentration of 50% saturated ammoniurn
sulfate. The gamma globulin fractions obtained by this proce-
dure and normal rabbit gamma globulin fractions were pair-
labeled with 131J and 12S1 radioactive iodine, and the amount cf
kidney-fixing antibody was quantitated by the paired-label
isotope technique [4, 5]. This technique was also used to
quantitate any effect of the inhibitors on the binding of anti-
body. The pooi of anti-GBM used in this study was the same as
that used in a previous study [2].
Micropuncture studies evaluating glomerular ultrafiltration
before and after anti-GBM. The micropuncture protocol used in
this study was nearly identical to that described in previous
studies on glomerular immune injury [1, 21. Surgical preparation
was as previously described, and all studies were paired with
iso-oncotic plasma expansion (2.5% body wt administered over
60 mm) as the control condition [I]. A separate infusion of '4C-
inulin dissolved in isotonic sodium chloride and sodium bicar-
bonate (0.5% body wt per hour) was begun at the time of plasma
expansion and was delivered at approximately 40 p.Ci/hr.
Control, group I. After the equilibration of radioactive inulirt,
initial measurements of glomerular capillary and Bowman's
space hydrostatic pressure (utilizing a servonulling device with
1- to 2-p.m tip pipettes) [1, 6] and of SNGFR (N = 5) were
obtained, and at least three samples of efferent peritubular
capillary blood from "star" vessels were obtained [61.
After completion of the first period measurements, a dose of
1.4 p.glg of body wt of anti-GBM was administered i.v. over 5
mm in a volume of 400 p.1 of isotonic sodium chloride and
sodium bicarbonate. Fifteen minutes after termination of antji-
GBM infusion, all pressure, filtration rate, and efferent protein
concentration measurements were repeated and completed
within 45 mm. In previous studies on the mechanism of
glomerular immune injury with anti-GBM, we determined that
inulin remains a valid marker of glomerular ultrafiltration after
the antibody is administered [I].
Infusion of sar'-ala8-AII, group 2. Surgical preparation,
inulin equilibration, and iso-oncotic plasma expansion were
identical to the protocol for the control group. An infusion of
sar'-ala8-AII, an All antagonist (1 p.g/kg of body wt/min Beck-
man Inst., Palo Alto, California), was initiated 30 mm prior to
the start of the first period of measurements and continued
throughout the course of the experiment. It was infused in an
isotonic sodium chloride and sodium bicarbonate solution (1 mg
per 10 ml). After completion of the first period measurements,
anti-GBM was administered using the same protocol as in the
control group, followed by a second period during which all
pressure, filtration rate, and efferent protein measurements
were repeated and completed within 45 mm.
Phentolamine infusion, group 3. Surgical preparation, inulin
equilibration, and iso-oncotic plasma expansion were identical
to the protocol for the control group. The infusion of phentol-
amine mesylate, an a-adrenergic blocker (27 p.g/kg of body wt/
mm, Regitine, CIBA Pharmaceuticals, Summit, New Jersey),
was initiated 30 mm prior to the start of the first period of
measurements and continued throughout the course of the
experiment. The phentolamine was infused in a small amount of
water (1.0 mg/mI). After completion of the first period measure-
ments, anti-GBM was administered using the same protocol as
in the control group, followed by a second period of measure-
ments. At the completion of the second period, the efficacy of
phentolamine infusion was evaluated with a bolus infusion of
phenylephrine (6 p.g/min, Neo-Synephrine hydrochloride®,
Winthrop Laboratories, Div. Sterling Drug, New York, New
York) for 5 mm to verify that a-blockade was complete. This
dose of phenylephrine was previously determined to raise the
mean arterial pressure 30 to 40 mm Hg in this model without
phentolamine.
Analytic method,s. Protein concentration in systemic and
efferent peritubular blood samples was measured by a microa-
daptation of the Lowry protein method [6—91. SNGFR, GFR,
RPF, and RBF, and urine and plasma sodium and potassium
concentrations were determined as described in previous stud-
ies [1,2,6—8].
Morphologic studies. Tissue for histologic, immunofluores-
cent, and electron microscope studies was obtained from both
kidneys at the termination of the study and processed as
previously described [1,2, 10, 11]. The mean polymorphonucle-
ar leukocytes (PMN) per glomerulus was determined by light
microscopy by counting the PMN in 20 glomeruli of each
kidney of each rat. Morphologic grading was based on a 0 to 4+
scale [2]. On light microscope examination, the glomerular
capillary lumens appeared irregular with variable degrees of
encroachment, which is presumably related to the endothelial
abnormalities seen by electron microscopy as well as to PMN
infiltration. Electron micrographs were evaluated as to the
degree of endothelial separation, foot process fusion, and PMN
approximation to the GBM.
Studies on the effects of sar'-ala8-AII and phentola,nine upon
anti-GBM fixation, complement activity, and peripheral blood
cell counts. Measurements were made to determine that the
blockers did not influence the process of glomerular immune
injury indirectly by altering anti-GBM fixation (by altering the
basic mechanism or renal load of anti-GBM delivered), comple-
ment activity (as measured by CH50), or peripheral white blood
cell counts. With the paired labeled technique [4, 51, quantita-
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tive renal fixation of anti-GBM was evaluated in 3 rats in each
of the three groups: controls, rats receiving sar'-ala8-AIl, and
those receiving phentolamine. The doses of anti-All and phen-
tolamine used and the duration of drug infusion were identical
to those used in the physiologic studies. Complement activity
was measured by CR50 in 15 rats (3 control, 6 receiving anti-All
and 6 receiving phentolamine) in the final period. Blood sam-
ples were drawn before plasma volume expansion, after plasma
volume expansion, and finally 45 mm after drug infusion to
determine if these agents might have mediated their effects by
influencing complement activity [2], Peripheral white blood cell
counts were also measured and compared in 15 rats following
the protocol used for CH50 sampling (3 control, 6 with sar'-ala8-
All, and 6 with phentolamine). Previous studies have suggested
an important role for PMN in mediating a reduction in L0A with
glomerular immune injury [1, 21.
Calculations. Superficial nephron filtration fraction (SNFF),
single nephron renal plasma flow (RPF), afferent arteriolar
resistance (AR), and efferent arteriolar resistance (ER) and
oncotic pressure ('Tr) from protein concentration (C) were calcu-
lated as described in our previous publications [I, 6—8, 12—14].
The four factors that define the SNGFR—hydrostatic pres-
sure gradient acting across the glomerular membrane (P),
systemic oncotic pressure ('irA), glomerular permeability coeffi-
cient (LA), and rate of RPF—interrelate in the following
manner.
Because P — PBS, where PG is the directly measured
glomerular capillary hydrostatic pressure and PBS is the hydro-
static pressure in Bowman's space, the effective filtration
pressure (EFP) can be defined as follows:
EFP = — 'ii
where ii is the oncotic pressure. Oncotic pressures of systemic
protein samples (CA) and efferent arteriolar samples (CE) were
determined by the following relationship
= 1.74C + 0.28C2
which is a simplification of the empirical relationship defined by
Landis and Pappenheimer [15] 'ir = 2.lC + 0.16C2 + 0.009C3.
As a consequence of glomerular ultrafiltration, ir rises along
the length of the glomerular capillary (x*) as a result of the
increase in protein concentration (C). The mean EFP (EFP) is
defined as follows:
E= f (P —Jo
Changes in RPF modify the E11' profile along x by affecting
the rate at which protein is concentrated and the rate of rise in 'rr
along x1'.
The SNGFR can therefore be defined as follows:
SNGFR = LA x Fi
where L0A is the glomerular permeability coefficient and which
in turn is a product of the hydraulic conductivity (L) of the
glomerular membrane and A, the total filtering surface area of
the glomerular capillary.
Statistical analysis. The significance of data between states
before anti-GBM and after anti-GBM administration in all three
groups was determined by two-way analysis of variance and by
Student's t test where appropriate [16]. Linear regression
analysis was applied to compare PMN with SNGFR between
periods for all rats measured (N = 17) [17].
Results
Measurements were obtained both before and after anti-GBM
administration in the three groups studied—group 1, control
and anti-GBM only; group 2, sar'-ala8-AII infusion, which was
maintained before and after anti-GBM administration; and
group 3, phentolamine infusion, which was maintained before
and after anti-GBM administration. The anti-GBM dose used in
all three groups was 1.4 ig/g of body wt.
As previously noted [I, 2] there were no gross morphologic
changes on the kidney surface after anti-GBM administration,
although a slight decrease in firmness of the kidney was evident
in some animals.
Group 1: Control anti-GBM administration. The control
studies were performed in such a fashion as to be interspersed
in time sequence throughout the other two groups of studies.
The anti-GBM administration produced a significant decrease
in SNGFR (58 4 to 35 6 nI min g of kidney wF', P <
0.0001) (Table 1, Fig. 1). The mean RPF also significantly
decreased from 272 35 to 170 52 nI min g kidney wr' (P
< 0.0001) (Fig. I). The superficial nephron filtration fraction
increased numerically, but the change was not statistically
significant.
The hydrostatic pressure in Bowman's space (PBS) decreased
significantly from 20 I to 13 2 mm Hg (P < 0.05). The PG
remained unchanged after anti-GBM administration. The
glomerular hydrostatic pressure gradient (P) increased (36 I
to 42 1 mm Hg, P < 0.01) (Fig. 2), such that the overall effect
of hydrostatic forces on SNGFR was positive. The mean
efferent peritubular capillary pressure (HPF) decreased from 24
Ito 19 1 mm Hg (P < 0.01).
The afferent (AR) and efferent (ER) arteriolar resistances
increased after the anti-GBM administration (AR, 8 Ito 19
4 x l0 dynes sec cm5, P < 0.05; ER, 6 Ito 14 2 X iO
dynes sec cm5, P < 0.02), which is similar to the effects
produced by the higher anti-GBM dose (2.4 ig/g of body wt) in
an earlier study [2].
Afferent plasma protein concentration (CA) was identical in
both periods (6.1 0.3 vs. 6.0 0.3 g/dl), as was the efferent
plasma protein concentration (CE, 7.7 0.6 vs. 7.9 0.4 g!dl).
Both the mean systemic oncotic pressure (IrA) and the mean
efferent oncotic pressure (IrE) were unchanged between periods
(Table 1). The hematocrit, however, was increased significantly
by the anti-GBM dose (44 1 vs. 48 1, P < 0.05) a change not
observed in the previous two studies [1, 2],
The EFP did not increase significantly although there was a
numerical increase (9 2 vs. 15 3, P > 0.1). This contrasts
with previous studies on anti-GBM where EFP significantly
increased [1,2]. EFPE did not increase significantly, but was
significantly greater than zero (4 1 mm Hg, N = 18) before the
anti-GBM administration in all three groups. The SNGFR
decreased significantly and the was similar after anti-GBM
administration. This finding suggests that a reduction in LA
(Table 1) was the essential factor in decreasing SNGFR. This
finding is supported by two previous studies from this labora-
tory [1, 2]. The LA was reduced from 0.13 0.03 before to
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0.04 0.01 nI sec' g kidney wF' mm Hg after anti-GBM
administration (P < 0.02, Fig. 2).
Group 2: Continuous sar'-aIa8-AI1 infusion with anti-GBM
administration. This group received a sar1-ala8—AII infusion
throughout the course of the experiment. After anti-GBM
administration in this condition, the SNGFR decreased dramat-
ically (55 2 to 18 6 nI min g kidney wr', P < 0.0005)
(Fig. I). This decrease in SNGFR was statistically greater than
the effect following anti-GBM in the control group I (P < 0.01).
The decrease in RPF as depicted in Table I was also greater in
magnitude than that observed in the control group (P < 0.05,
Fig. I). The values for SNGFR and RPF in the pre-anti-GBM
condition in groups I and 2 were not significantly different. This
indicates a modifying influence of sar'-ala8-AI1 on the effects of
anti-GBM. The superficial nephron filtration fraction was un-
changed by the administration of the antibody (Table I).
The hydrostatic pressure of Bowman's space (PBS) was
significantly reduced (20 Ito 11 1 mm Hg, P <0.01) after
anti-GBM administration. This reduction in pressure during
sar'-ala8-A1I infusion was statistically the same as that ob-
served in the control group. The glomerular hydrostatic pres-
sure (PG) and the glomerular hydrostatic pressure gradient (P)
were unchanged by administration of anti-GBM (Table 1) (Fig.
2). HPE was reduced from 23 2 to 17 2 mm Hg (P < 0.05)
after antibody administration, similar to the decrease demon-
strated in the control group.
The afferent (AR) and efferent (ER) arteriolar resistances
were numerically different between the two periods, but due to
a large standard error, the differences were not statistically
significant (Table I). In certain animals. nephron and renal
blood flow were negligible after anti-GBM during sar'-ala8-Afl
infusion. If afferent conductances were compared (1/AR) the
difference between periods was significant (P < 0.01), but the
elferent conductance was not significantly different.
The protein concentration during sar'-ala8-AII infusion was
unchanged by antibody administration (CA, 6.2 0.3 to 6.3
0.2 g/dl, NS; CE, 8.1 0.2 to 8.6 0.2 g/dl, NS). The mean
systemic afferent (ITA) and efferent (IrE) oncotic pressures were
unchanged between measurement periods and were quite simi-
lar to the values for the control group (Table 1). The hematocrit,
however, did change. It increased from 43 Ito 50 1% (P <
0.01). This finding is similar to the increase that was observed in
the control group 1.
The mean effective filtration pressure (EFP) did not change
between periods (9 3 to 10 2, NS). There was no significant
change in the EFPE or EFPA after anti-GBM administration.
But, the EFPF was numerically lower during sar-a1a8-AIZ[
infusion and anti-GBM (4 2 mm Hg) than was observed in
group 1 (10 3 mm Hg).
During sar'-ala8-AII infusion, LA decreased 0.17 0.05 to
0.04 0.01 nI sec g kidney wr' mm Hg (P <0.05) (Fig.
2). As in group I, the SNGFR was significantly reduced
whereas the EFP remained the same, indicating that a decrease
in LA was the essential contributing factor to the reduction in
SNGFR.
The sar'-ala8-AII infusion had no effect on the determinants
of nephron filtration in the pre-anti-GBM state. This conclusion
is supported by the similarity of the pre-anti-GBM condition in
the control group and the sar'-ala8-AII infusion group. A recent
study from this laboratory has demonstrated that sar'-ala8-AIIL
produces no effects in a rat receiving a normal sodium chloride
intake [141. Sar'-ala8-AII infusion enhanced the effect of the
increased vasoconstriction that was induced by anti-GBM, as
the dramatic reduction in SNGFR, RPF, and RBF (432 50 to
103 45 nI mind g kidney wr', P < 0.0001) clearly
demonstrate.
Group 3: Continuous phentolamine infusion with anti-GBM
administration. Qualitatively, phentolamine had no obvious
effect on the appearance of the kidney prior to antibody
administration.
During anti-GBM administration (5 mm), the kidney ap-
peared to pulsate, and there was a transient decrease in blood
pressure only in the phentolamine infusion group. The mean
arterial pressure returned to the preinfusion values, and the
arterial pulsations diminished after anti-GBM administration
was completed. A potential explanation for these events is that
phentolamine might unmask the concurrent release of a vasodi-
lator substance associated with glomerular immune injury.
The results during phentolamine infusion with anti-GBM
were quite different from those observed in the previous two
groups. The SNGFR did not change significantly after the anti-
GBM administration (52 3 to 52 4 nl mini g kidney wt,
NS) (Fig. 3). This result was significantly different from the
changes observed in control group I (SNGFR of Group I vs.
SNGFR of Group 3, P < 0.01) and the sar'-ala5-AII infused
group 2 (SNGFR of group 2 vs. SNGFR of group 3. P <
0.01).
The pre-anti-GBM values in the phentolamine group were
statistically not different from those in the control group I or in
the group 2. The values for RPF and RBF for phentolamine did
not differ significantly in the pre-anti-GBM state from the other
two groups. Although the numerical value for the RPF in the
first measurement period of phentolamine was lower (206 nl/
mm) than that of the other groups (272 nI/mm, control; 247 nl/
mm, group 2), it was statistically not different. This value for
RPF (206 nI/mm) is in fact quite consistent with values (range,
190 to 280 nI/mm for group means) reported for the pre-anti-
GBM period in two previous studies from this laboratory II, 2]
using identical plasma expansion protocols. The RPF as earlier
noted did not change significantly after anti-GBM administra-
tion during phentolamine infusion (206 16 to 222 15 nI mm
g kidney wt) (Fig. 3). The directional changes in RPF (RPF)
after anti-GBM in groups 1 and 2 were both significantly different
(P < 0.01) from the directional change during phentolamine. The
SNFF did not change after anti-GBM in group 3.
The hydrostatic pressure of Bowman's space (PBS) was not
altered by the administration of anti-GBM Ab in the phentol-
amine-infused rat (Table 1), a finding considerably different
from the previous two groups. P and P were also unchanged
(Fig. 4) between periods.
Vascular resistances were similar before and after anti-GBM
infusion. Afferent arteriolar resistance (AR) was 10 I in the
control period and 9 1 x l0 dynes sec cm after anti-
GBM. Efferent arteriolar resistance was not altered by infusion
of anti-GBM (Table I). This lack of change in critical parame-
ters after anti-GBM was quite different from the changes in
resistances observed in groups I and 2.
Afferent plasma protein concentration (CA) did not change
after anti-GBM, but efferent protein concentration (CE) did
decrease significantly (8.1 0.3 to 7.1 0.3 g/dl, P < 0.05).
Pre-antj.GBM Post-anti-GBM
Fig. 1. Effects of an:i-GBM administration upon SNGFR and RPF in
control group 1 (0) rats and in group 2 receiving continuous infi?sion of
sar'-alaAII (A), the All antagonist. The reductions in SNGFR and
RPF were significant (*) in both groups but significantly greater in group
2.
Systemic oncotic pressure (IrA) did not change significantly,
although there was a numerical reduction. The decrease in ir1
was statistically significant (32 2 to 27 2 mm Hg, P < 0.02).
The hematocrit remained identical in both periods, which was
not the case in groups I and 2.
Phentolatnine effects on EFP and L,,A. The EFP increased
numerically from 10 1 mm Hg before antibody administration
to 15 2 mm Hg (N = 6) after anti-GBM was administered, but
these values were not statistically different. The EFP values
after anti-GBM administration were statistically higher than they
Preant-GBM Post-ant-GBM
Fig. 2. Effects of anti-GBM administration upon glomerularpermeabili-
ty coefficient (LA) and hydrostatic pressure gradient across glomeru-
br membrane (AP) in control group 1 (0) and in group 2 receiving
continuous infusion of sar'-ala8-AlI (A), the All antagonist. The
reductions in LA were significant and similar in both groups. AP
increased significantly after anti-GBM administration only in the con-
trol group 1.
were before its administration (9 I, N = 18, vs. 15 2, N6,
P < 0.05). The same comparison was made for both groups 1
and 2 after anti-GBM administration. There were no statistical
differences with the combined pre-anti-GBM Ab values (N
18).
The LA was decreased numerically from 0.10 0.02 to 0.07
0.01 n1 sec g kidney wt mm Hg', N = 6, after anti-
GBM administration. This was not a statistically significant
change. When the experimental (post-anti-GBM) period is
compared with a composite of pre-anti-GBM values from all
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Table 1. Effect of sar'-ala8-angiotensin II infusion and phentolamine infusion on pressures, flows, permeabilities, and resistances before and
after antiglomerular basement membrane antibody administration
MAP
mm Hg
GFR
milminig
kidney
P(;
mm Hg
P,,.
mm Hg Inn?
P
Hg
HP
mm Hg
SNGFR
nl min
g kidney
RPF
ni mm'
kidney'
g
Pre Post Pre Post Pie Post Pre Post Pre Post Pre Post Pre Post Pre Post
Group 1: Control 105 106 1.4 1.0 56 54 20 13" 36 42" 24 19" 58 35" 272 170"
(N=6) ±5 ±3 ±0.1 ±0.2 ±1 ±2 ±1 ±2 ±1 ±1 ±1 ±2 ±4 ±6 ±35 ±52
Group 2: Sar'-ala8- 97 98 1.4 0.4" 57 50 20 II" 37 40 23 17" 55 18" 247 68"
Allinfusion(N=6) ±3 ±3 ±0.1 ±0.1 ±2 ±2 ±1 ±1 ±2 ±2 ±2 ±2 ±2 ±6 ±28 ±24
Group 3: 99 97 1.2 1.2 55 54 19 17 36 37 24 22 52 52 206 222
Phentolamine ±2 ±3 ±0.1 ±0.1 ±2 ±1 ±2 ±1 ±1 ±1 ±2 ±1 ±3 ±4 ±16 ±15
infusion (N = 6)
Pre and post refer to pre.anti-GBM and post-anti-GBM administration. Abbreviations are defined in text.
different from pre-anti-GBM period, P < 0.05
Values are the means ± SEM,
b Post-anti-GBM period significantly
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Table 1. (Continued)
o
Pre.anti-GBM Post-anti-GBM
Fig. 3. Effects of anti-GBM administration upon SNGFR and RPF in
control group 1(0) rats and in group 3 receiving continuous infusion of
phentolamine (0), the cx-adrenergic blocker. Phentolamine infusion in
group 3 rats prevented the reduction in both SNGFR and RPF observed
in control group I after anti-GBM administration.
three groups, there is a statistically significant decrease (0.13
0.02, N = 18, vs. 0.07 0.01 n1 sec Lgkidney wr1 mm Hg
N = 6. P < 0.02). This comparison is valid due to the statistical
similarity of all three groups during the pre-anti-GBM period.
Although the LA in the phentolamine group decreases after
anti-GBM administration, the decrease is less than that of the
other two groups, indicating a partial beneficial effect of phen-
tolamine on LA.
immunopathologic studies. Histologic studies in all groups
demonstrated changes similar to those previously noted [1, 2]
and consisted predominantly of PMN accumulation and endo-
thelial separation with only mild and focal fusion of epithelial
foot processes (Fig, 5). Occasional monocytes were also seen in
RBF
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Fig. 4. Effects of anti-GBM administration upon LA and P in control
group 1 (0) rats and in group 3 receiving continuous infusion of
phentolamine (Li), the a-adrenergic blocker. Phentolamine infusion in
group 3 rats prevented the reduction in LA that was observed in
control group I after anti-GBM administration. Also, P did not change
in group 3 rats.
glomerular capillary lumens. The changes in the phentolarnine
group were perhaps slightly less, but consistent differences
between the groups were not apparent. The moderate increase
of PMN was observed within the glomerular capillary lumen
and was quantitated. A mean of 7.7 ± 1.2 PMN (N = 6) was
found in the sar'-alat-AII group, 4.8 ± 0.9 PMN (n = 6) in the
phentolamine group, and 4.9 ± 1.2 PMN (N = 6) in the control
group (table 2). Due to individual variations, the differences in
PMN counts between groups did not reach statistical signifi-
cance. There was a relationship between the mean PMN count
and the depression of SNGFR (SNGFR) for all groups (Table
2) (N = 17), but not ihe decrease in LA. The inhibitors did not
cause any detected difference in antibody binding, complement
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Fig. 5. Polymorphonuclear leukocytes (PMN). A PMN (arrows) are seen in the glomerulus of a rat from the sar'-ala5-AlI group. B Linear rabbit lgG
deposits of anti-GBM antibody are present in a similar animal. C A PMN is seen displacing the endothelium (EN) of another rat in this group. EP is
epithelial cell. (Original magnification for A and B, x250; for C, >< 12,300).
activity, circulating WBC counts, platelets, or percentage cell
types. The antibody binding was measured in a separate group
of rats, by the pair-label isotope technique [4, 5].
There was no statistical difference in the specific percent
binding of 100 g of radiolabeled anti-GBM globulin in the three
groups (group I, 1.86 0.05, N = 2; group 2, 1.88 0.03, N =
3; group 3, 1.84 0.04, N = 3).
The effects of sar'-ala8-AII and phentolaminc on the comple-
ment level was determined in another group of rats. The CH0 was
determined in paired experiments after plasma expansion, 45 mm
after infusion of drugs (sar'-ala8-AII, N = 6, and phentolamine, N
= 6) or isotonic sodium chloride and sodium bicarbonate solution
(control, N = 3). There was no detectable difference between
periods or between experimental groups. The preplasma expan-
sion measurements made in two groups (sar'-ala8-Al1, N = 3;
phentolamine, N =3) were not different from the postexpansion
measurements. The circulating white blood cells, platelets, and
percentage cell types were measured in the rats used for the CHS()
determinations following the same protocol. The WBC counts
were elevated after the plasma expansion in all groups (5800 200
in hydrophenia vs. 10,500 100 with plasma expansion, N = 15,
P < 0.01). The WBC counts were not statistically different from
the plasma expanded values after the sodium chloride and sodium
bicarbonate infusion (9800 1200, N = 2), the sar'-ala8-A1l
infusion (12,000 1,900, N=6), or the phentolamine infusion
(8000 1000, N = 6). The platelet counts decreased significantly
after plasma expansion (7.97 X l0 0.20 X l0 in hydropenia vs.
7.25 x l0 0.24>< l0 in plasma expansion, N = 15, P < 0.05).
The counts were not altered from the plasma expansion values by
the infusion of sodium chloride and sodium bicarbonate solution
(7.63 x l0 0.23 x l0, N = 3), sarLala8AII (7.04 x l0 0.30
x 1O, N=6), or phentolamine (7.31 x l0 0.38 x lOs, N = 6).
There was also no significant difference in the percentage of
PMN's or lymphocytes after infusion of the inhibitors or in the
control rats.
Discussion
The participation of the renin angiotensin and adrenergic
nervous systems in the process of glomerular immune injury
has been examined in the present study by using the blockers of
All and ct-adrenegic activity (sar'-ala8-All and phentolamine).
It is clear from the present data that inhibition of the intrarenal
action of All in no manner prevents either the reduction in
nephron plasma flow or the decrease in the glomerular perme-
ability coefficient, which has been shown to follow the adminis-
tration of large doses of anti-GBM. Examination of these data
actually reveals that the concomitant infusion of sar'-ala5-AII
results in a greater reduction in both SNGFR and RPF following
antibody administration than was observed in the untreated
control group. Phentolamine infusion, however, completely
•
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prevented a reduction in RPF after anti-GBM and partially
diminished the effects of the antibody upon LA.
A full explanation of the specific mechanisms that produce
the reduction in RPF after anti-GBM is not feasible from the
present data. Previous studies have demonstrated that the
vasoconstriction observed is complement dependent because
complement depletion almost totally prevented the reduction in
RPF at both low and very high doses of anti-GBM [2]. Adminis-
tration of phentolamine in this study also completely prevented
the reduction in RPF associated with glomerular immune inju-
ry. This response certainly suggests that some expression of a-
adrenergic activity is functioning in this inflammatory mecha-
nism. The complement cascade or some specific component
thereof could either activate a-adrenergic receptors indirectly
or some complement component could interact directly with an
a-adrenergic receptor. Regardless of the specific mechanism, it
is clear from the present and previous data that the complement
system, probably acting via a-adrenergic vascular receptors, is
involved in the reduction in RPF after anti-GBM administration
and that this aspect of glomerular immune injury can be wholly
prevented by cs-adrenergic blockade.
The effect of sar'-alat-AII that was observed is somewhat
more difficult to explain in detail. The reduction in RPF after
anti-GBM during sar'-ala8-AIl infusion was definitely greater
than that observed in the untreated control group. We have not
observed a true agonist effect of sar'-ala8-AIl in the plasma
expanded rat, a conclusion supported by the comparison of the
RPF, AR, and ER values prior to anti-GBM administration in
all groups.
Sar'-ala8-AII infusion did not, however, affect the reduction
in LA following anti-GBM. Quantitatively, the decrease in
LA consequent to anti-GBM was quite similar in both sart-
ala8-AIl and control groups. These data then suggest that
although sar'-ala8-AlI infusion enhanced the immune-induced
vasoconstriction, this agent apparently had no influence on the
decrease in LA [181. Although the data provided in the study
do not permit specific conclusions about the mechanism, we
would speculate that two possibilities are not unreasonable.
First, sarLala8AII like All may have a significant effect on
catecholamine release and reuptake [19, 201 and could magnify
a-adrenergic-mediated vasoconstriction, or second, sar'-ala8-
All may somehow diminish the role of some vasodilator system
normally activated during glomerular immune injury.
In previous studies from this laboratory, we have associated
the reduction in L.A after anti-GBM with two morphologic
findings: (1) the separation of the endothelial cell from the
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Table 2. Correlation of changes in SNGFR with polymophonuclear leukocyte (PMN) accumulation in the glomerulus
Pre-anti-GBM SNGFR Pot-anti-GBM SNGFR Change in SNGFR
nI - mm g kidney wi ' ni g kidney ut
17
Percent determined as SNGFR/pre-anti-GBM SNGFR.
h ND denotes no data available for PMN/glomerulus. experiment #13, hence N
P value is for correlation with PMN/glomerulus by linear regression analysis.
17 used for correlations.
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underlying GBM and (2) the migration of polymorphonuclear
leukocytes (PMN) into the glomerular capillary and their at-
tachment to the underlying GBM after removal of the endotheli-
a! cell [1, 2].
Based on our previous study with complement depletion, we
can say that the elimination of the complement cascade pre-
vented accumulation and attachment of PMN's, but did not
influence separation of the endothelial cell, a finding that
appeared to relate primarily to fixation of anti-GBM and not to
activation of complement [21. An unexpected finding provided
by the data of this study is that phentolamine infusion (group 3)
also appears to have partially prevented much of the reduction
in LA observed in groups I and 2 after anti-GBM administra-
tion.
The LA values in a paired determination in the phentolamine
group before and after anti-GBM exhibited no statistically
significant change. But, when the pre-anti-GBM LA values for
all three groups were combined (0.13 0.02, N = 18), the LA
decreased significantly. Although the LA was less affected by
anti-GBM in the phentolamine group, the results indicate only a
partial beneficial effect of a-adrenergic blockade upon the
reduction in LA with glomerular immune injury. No definite
differences in the degree of endothelial cell separation were
detected among the groups, and this may explain the modest
reduction in LA that was observed after anti-GBM in group 3.
In addition, there was no morphologic finding unique to group 3
or prevented by phentolamine infusion. The only association
observed was that the number of PMN's accumulated within
glomeruli after anti-GBM correlated reasonably well with the
magnitude of reduction in SNGFR when all experimental
animals were analyzed (N = 17).
It is tempting to speculate that any drug effects on the degree
to which LA decreases after anti-GBM administration might
be also mediated by effects on the PMN 121, 25], but the
morphologic finding of decreased PMN 's was not unique to the
phentolamine-treated group.
The numerically lower but not statistically different value for
RPF in the control condition in group 3 also does not explain
this effect of phentolamine on LA. Specific studies examining
the binding of anti-GBM demonstrated that phentolamine infu-
sion did not decrease the quantity of anti-GBM bound to the
renal tissue. More recent data from our laboratory have also
shown that if control RPF is decreased to values (208 nI/mm)
nearly identical to that observed with phentolamine via the
infusion of cimetidine, a histamine-2 (H-2) receptor blocker, the
magnitude of reduction in LA after anti-GBM administration is
in no way diminished and antibody binding is unaltered [26].
Activity of the complement system, as evaluated by blood CH50
and glomerular deposits of C3 as determined by immurtofluores-
cence, was also unaffected by phentolamine infusion.
Obviously, further more specific studies are required to fully
delineate the details of phentolamine effects on this early phase
of immune injury in the glomerulus. It will also be of interest to
determine if a-adrenergic blockade provides a significant and
pronounced beneficial effect at later stages of this model of
glomerular immune injury.
We have also recently observed that infusion of the H-2
receptor antagonist cimetidine also prevents changes in afferent
and efferent arteriolar resistance following anti-GBM in this
same experimental model, but this agent did not alter the
magnitude of reduction in LA [26]. How these expressions of
a-adrenergic activity and H-2 receptor activity might interact in
this model and whether this interaction is specific or nonspecif-
ic is not known.
The present studies suggest that concurrent infusion of sar'-
ala8-AII and phentolamine, inhibitors of All and a-adrenergic
activity, respectively, have reasonably profound, but differing
influences on the multiple effects resulting from the acute
infusion of anti-GBM. Sar'-ala8-AII infusion magnifies, and
phentolamine infusion prevents much of the immune induced
vasoconstriction. These drug effects seem to be mediated via
their respective influences on a-adrenergic activity. A surpris-
ing and interesting, but possibly less specific, finding is the
beneficial influence of phentolamine infusion in preventing in
major part the immune-induced reduction in the glomerular
permeability coefficient (LA). It is apparent that multiple
biologic systems contribute to the complex mechanisms pro-
ducing glomerular immune injury.
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